Prometheus Biosciences Inc (RXDX)

With a $1.5 billion market value, Ignyta Inc (NASDAQ:RXDX) ranks in the top quarter of its industry group, Biotechnology, and in the upper half of its sector group, Health Care, in market value. From the prospective of investment attractiveness, Portfolio Grader's current ranking for RXDX puts it 57 among the 351 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 139 among the 781 companies in the sector, and number 800 in the nearly 5,000 company Portfolio Grader universe.

Currently, Ignyta Inc (NASDAQ:RXDX) has a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for the last month.